Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -8.0x - -8.9x | -8.5x |
| Selected Fwd P/E Multiple | -10.1x - -11.2x | -10.6x |
| Fair Value | A$0.34 - A$0.38 | A$0.36 |
| Upside | 17.9% - 30.3% | 24.1% |
| Benchmarks | - | Full Ticker |
| Genetic Signatures Limited | - | ASX:GSS |
| Trajan Group Holdings Limited | - | ASX:TRJ |
| Genetic Technologies Limited | - | ASX:GTG |
| OncoSil Medical Limited | - | ASX:OSL |
| Memphasys Limited | - | ASX:MEM |
| Proteomics International Laboratories Ltd | - | ASX:PIQ |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| GSS | TRJ | GTG | OSL | MEM | PIQ | |||
| ASX:GSS | ASX:TRJ | ASX:GTG | ASX:OSL | ASX:MEM | ASX:PIQ | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | -25.2% | -1600.4% | -2.3% | -7.7% | -12.9% | -20.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -42.6% | -1.6% | -12701.2% | -688.4% | -522.5% | -148.7% | ||
| Prior Fiscal Year | -65.3% | 1.2% | -113.6% | -773.0% | -545.0% | -194.2% | ||
| Latest Fiscal Year | -129.7% | -16.3% | -124.2% | -761.1% | -407.6% | -194.6% | ||
| Latest Twelve Months | -121.1% | -17.8% | -124.2% | -659.9% | -475.2% | -203.4% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | -3.1x | 14.3x | -5.0x | -0.6x | -3.7x | -6.3x | ||
| Price / LTM Sales | 4.6x | 0.7x | 5.4x | 8.6x | 9.2x | 13.6x | ||
| LTM P/E Ratio | -3.8x | -3.9x | -4.3x | -1.3x | -1.9x | -6.7x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -4.3x | -3.8x | -1.3x | |||||
| Historical LTM P/E Ratio | -36.9x | -21.5x | -17.3x | |||||
| Selected P/E Multiple | -8.0x | -8.5x | -8.9x | |||||
| (x) LTM Net Income | (7) | (7) | (7) | |||||
| (=) Equity Value | 57 | 60 | 63 | |||||
| (/) Shares Outstanding | 163.5 | 163.5 | 163.5 | |||||
| Implied Value Range | 0.35 | 0.37 | 0.39 | |||||
| FX Rate: AUD/AUD | 1.0 | 1.0 | 1.0 | Market Price | ||||
| Implied Value Range (Trading Cur) | 0.35 | 0.37 | 0.39 | 0.29 | ||||
| Upside / (Downside) | 20.6% | 27.0% | 33.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GSS | TRJ | GTG | OSL | MEM | PIQ | |
| Value of Common Equity | 86 | 111 | 52 | 16 | 10 | 47 | |
| (/) Shares Outstanding | 227.1 | 152.4 | 1,335.4 | 14.2 | 1,983.6 | 163.5 | |
| Implied Stock Price | 0.38 | 0.73 | 0.04 | 1.16 | 0.01 | 0.29 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.38 | 0.73 | 0.04 | 1.16 | 0.01 | 0.29 | |
| Trading Currency | AUD | AUD | AUD | AUD | AUD | AUD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |